Traders Purchase Large Volume of Call Options on Zoetis (ZTS)
Zoetis Inc. (NYSE:ZTS) saw unusually large options trading activity on Wednesday. Stock traders bought 25,516 call options on the company. This represents an increase of approximately Infinity compared to the average volume of 0 call options.
A number of hedge funds have recently made changes to their positions in ZTS. Janus Henderson Group PLC raised its position in Zoetis by 7,717.4% in the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after acquiring an additional 5,734,776 shares during the period. Alliancebernstein L.P. raised its position in Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after acquiring an additional 3,695,449 shares during the period. Waddell & Reed Financial Inc. raised its position in Zoetis by 65.9% in the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock worth $290,033,000 after acquiring an additional 2,157,803 shares during the period. BlackRock Inc. raised its position in Zoetis by 3.9% in the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after acquiring an additional 1,412,829 shares during the period. Finally, AJO LP raised its position in Zoetis by 4,506.8% in the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock worth $79,311,000 after acquiring an additional 1,243,826 shares during the period. 93.04% of the stock is currently owned by institutional investors and hedge funds.
Zoetis (NYSE ZTS) opened at $68.69 on Friday. The company has a debt-to-equity ratio of 2.13, a quick ratio of 1.17 and a current ratio of 2.01. The firm has a market cap of $32,799.38, a price-to-earnings ratio of 30.88, a price-to-earnings-growth ratio of 2.01 and a beta of 1.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 66.15%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm earned $0.52 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. analysts anticipate that Zoetis will post 2.36 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s dividend payout ratio is 22.11%.
A number of equities research analysts have commented on ZTS shares. Cowen and Company set a $60.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Deutsche Bank AG reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, July 21st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. Finally, Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $67.06.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.